David Nierengarten
Stock Analyst at Wedbush
(3.75)
# 757
Out of 4,984 analysts
203
Total ratings
46.63%
Success rate
9.16%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $3.27 | +83.49% | 10 | Sep 8, 2025 | |
| NUVL Nuvalent | Reiterates: Outperform | $115 | $78.33 | +46.81% | 6 | Sep 8, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $2.14 | +86.92% | 1 | Sep 8, 2025 | |
| XNCR Xencor | Reiterates: Outperform | $26 | $8.62 | +201.62% | 8 | Sep 2, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $9.42 | +133.55% | 3 | Aug 28, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $9.99 | +150.25% | 1 | Aug 18, 2025 | |
| GBIO Generation Bio Co. | Downgrades: Neutral | $7 | $5.95 | +17.65% | 9 | Aug 13, 2025 | |
| VOR Vor Biopharma | Reiterates: Neutral | $0.4 | $1.57 | -74.52% | 8 | Jun 26, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $752.32 | -4.96% | 21 | Jun 24, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.27 | +236.39% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $12.27 | -18.50% | 10 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $12.68 | +112.93% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $34 | $35.77 | -4.95% | 3 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $9.09 | +263.04% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.89 | +124.32% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $0.95 | +425.93% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $11.25 | +175.56% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $19.39 | +106.29% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $36.84 | +144.30% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $32.34 | +45.33% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $8.61 | +167.13% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $10.90 | +83.49% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $14.90 | +168.46% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $14.82 | +203.64% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.72 | +481.40% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $2.37 | +659.49% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $60.34 | -5.54% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $12.54 | -20.26% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.67 | +156.96% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $22.91 | +148.80% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $7.21 | +2,327.18% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.95 | +12,558.23% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $6.26 | +858.47% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.85 | +114.69% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $29.48 | +154.41% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.15 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.25 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.16 | - | 3 | Nov 20, 2017 |
Nuvation Bio
Sep 8, 2025
Reiterates: Outperform
Price Target: $6
Current: $3.27
Upside: +83.49%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $78.33
Upside: +46.81%
Shattuck Labs
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $2.14
Upside: +86.92%
Xencor
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $8.62
Upside: +201.62%
Telix Pharmaceuticals
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $9.42
Upside: +133.55%
BridgeBio Oncology Therapeutics
Aug 18, 2025
Initiates: Outperform
Price Target: $25
Current: $9.99
Upside: +150.25%
Generation Bio Co.
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $5.95
Upside: +17.65%
Vor Biopharma
Jun 26, 2025
Reiterates: Neutral
Price Target: $0.4
Current: $1.57
Upside: -74.52%
argenx SE
Jun 24, 2025
Reiterates: Outperform
Price Target: $715
Current: $752.32
Upside: -4.96%
Perspective Therapeutics
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.27
Upside: +236.39%
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $12.27
Upside: -18.50%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $12.68
Upside: +112.93%
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $35.77
Upside: -4.95%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $9.09
Upside: +263.04%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.89
Upside: +124.32%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $0.95
Upside: +425.93%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $11.25
Upside: +175.56%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $19.39
Upside: +106.29%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $36.84
Upside: +144.30%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $32.34
Upside: +45.33%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $8.61
Upside: +167.13%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $10.90
Upside: +83.49%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $14.90
Upside: +168.46%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $14.82
Upside: +203.64%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.72
Upside: +481.40%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $2.37
Upside: +659.49%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $60.34
Upside: -5.54%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $12.54
Upside: -20.26%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.67
Upside: +156.96%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.91
Upside: +148.80%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $7.21
Upside: +2,327.18%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.95
Upside: +12,558.23%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $6.26
Upside: +858.47%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.85
Upside: +114.69%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $29.48
Upside: +154.41%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.15
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.25
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.16
Upside: -